Photodynamic therapy

Levy, Julia G.

doi:10.1016/s0167-7799(00)88895-2

Cited by 92 publications

(74 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Benzoporphyrin derivative monoacid ring A (BPD-MA, verteporfin) (8 -10), a lipophilic chlorin-like photosensitizer with a maximum light absorption peak at 690 nm, is currently undergoing clinical evaluation for the treatment of a number of pathological conditions including age-related macular degeneration, skin cancer, psoriasis, and rheumatoid arthritis (11,12). Pretreatment of skin grafts with subtoxic levels of verteporfin and light prolonged their acceptance on allogeneic recipients (13).…”

Section: P Hotodynamic Therapy (Pdt)mentioning

confidence: 99%

IL-10 Contributes to the Inhibition of Contact Hypersensitivity in Mice Treated with Photodynamic Therapy

Simkin

Tao

Levy

et al. 2000

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

We have explored the effect of photodynamic therapy (PDT) with verteporfin on the induction and expression of contact hypersensitivity (CHS) to 2,4-dinitrofluorobenzene (DNFB) in normal mice and IL-10-deficient mice. Our results indicate that DNFB sensitized mice given PDT with verteporfin and whole body red light irradiation exhibited a significant reduction in CHS compared with control animals. Administration of rIL-12 reversed the effect(s) of PDT as did treatment of mice with anti-IL-10-neutralizing Ab. Knockout mice deficient in IL-10 were found to be resistant to the inhibitory effects of PDT. In vitro proliferative responses using spleen cells from DNFB-sensitized and PDT-treated mice showed a significantly lower response to DNBS as compared with cells from DNFB-sensitized mice or DNFB and PDT-treated IL-10-deficient mice. Finally, naive mice exposed to PDT exhibited an increase in skin IL-10 levels, which peaked between 72 and 120 h post-PDT. Together these data support the role of IL-10 as a key modulator in the inhibition of the CHS response by whole body PDT.

show abstract

Section: P Hotodynamic Therapy (Pdt)mentioning

confidence: 99%

IL-10 Contributes to the Inhibition of Contact Hypersensitivity in Mice Treated with Photodynamic Therapy

Simkin

Tao

Levy

et al. 2000

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…PDT is also under investigation for the treatment of other ocular disorders as well as atherosclerosis, restenosis, allograft rejection, and autoimmune disorders. 1 PDT catalyzes the formation of reactive oxygen intermediates and rapidly induces apoptosis in a variety of cell types after light irradiation. [2][3][4][5] In vivo studies have shown that PDT represents a safe, effective method of inhibiting the development of intimal hyperplasia.…”

mentioning

confidence: 99%

Mitochondrial Release of Apoptosis-Inducing Factor and Cytochrome c During Smooth Muscle Cell Apoptosis

Granville

Cassidy

Ruehlmann

et al. 2001

The American Journal of Pathology

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is under investigation for the treatment of intimal hyperplastia in conditions such as atherosclerosis and restenosis. Although smooth muscle cells (SMCs) may be a key target for treatment, the effects of PDT on these cells are poorly characterized. In the present study, apoptosis was induced in primary human aortic SMCs by the combination of the photosensitizer verteporfin and visible light. After PDT, an increase in mitochondrial cytochrome c (cyt c) and apoptosis-inducing factor (AIF) levels were detected in the cytosol immediately and their levels increased steadily up to 2 hours. Cytosolic levels of the pro-apoptotic Bcl-2 family member Bax decreased reciprocally throughout this period, but this change did not occur before cyt c release. Confocal microscopy revealed a diffuse staining pattern of cyt c within apoptotic cells as compared to a distinct mitochondrial staining in normal cells. AIF translocated from mitochondria to the nucleus during the progression of apoptosis. After cyt c release, caspase-9 and caspase-3 processing was visible by 1 hour and caspase-6, -7, and -8 processing was apparent by 2 hours after PDT. In summary, these results demonstrate for the first time the cellular redistribution of mitochondrial AIF during SMC apoptosis, as well as the early release of cyt c and the subsequent activation of multiple caspases during PDT-induced SMC apoptosis. Photodynamic therapy (PDT) is a clinically approved treatment for various types of cancer and the ocular condition known as age-related macular degeneration, the leading cause of blindness in the elderly. PDT is also under investigation for the treatment of other ocular disorders as well as atherosclerosis, restenosis, allograft rejection, and autoimmune disorders. 1 PDT catalyzes the formation of reactive oxygen intermediates and rapidly induces apoptosis in a variety of cell types after light irradiation. [2][3][4][5]

show abstract

“…If the photoexcited dyes are capable of in situ energy or electron transfer, they can also be used as sensitisers for the photodynamic therapy (PDT) of tumours. The most widely studied dye for PDT, Photofrin (Pll), consists of a mixture of haematoporphyrin derivatives, and this preparation has been approved for clinical use (Levy, 1995). However, the relatively low absorbance above 600 nm (at which tissues provide optimal transparency) and some pharmacodynamic drawbacks have led to the development of new dyes for PDT (Morgan et al., 1988; van Lier, 1988).…”

mentioning

confidence: 99%

Serum albumin as a vehicle for zinc phthalocyanine: photodynamic activities in solid tumour models

Larroque

Pèlegrin²,

Lier³

1996

Br J Cancer

View full text Add to dashboard Cite

Summary Zinc phthalocyanine (ZnPc) is a second-generation photosensitiser for the photodynamic therapy (PDT) of cancer. Unsubstituted ZnPc is, however, highly insoluble in most common solvents, and for clinical applications the material needs to be incorporated in liposomes. We report a simple, alternative procedure to formulate ZnPc through non-covalent binding to bovine serum albumin (BSA). Intravenous administration of ZnPc-BSA preparations, at a molar ratio of 11: 1 and at a ZnPc dose equivalent to 0.5 mol kg-, to tumourbearing mice followed 24 h later by PDT was shown to provide tumour control in two different models, the EMT-6 tumour in Balb/c mice and the human colon T380 carcinoma in nude mice. Analysis of serum fractions from treated animals showed that ZnPc readily redistributes over the serum high-density lipoprotein (HDL) fraction. We also demonstrated the absence of hepatic toxicity of the ZnPc-BSA preparation by monitoring the hepatic cytochrome P450 activiy in treated animals and the viability of human cultured hepatocytes.

show abstract

Photodynamic therapy

Cited by 92 publications

References 14 publications

IL-10 Contributes to the Inhibition of Contact Hypersensitivity in Mice Treated with Photodynamic Therapy

IL-10 Contributes to the Inhibition of Contact Hypersensitivity in Mice Treated with Photodynamic Therapy

Mitochondrial Release of Apoptosis-Inducing Factor and Cytochrome c During Smooth Muscle Cell Apoptosis

Serum albumin as a vehicle for zinc phthalocyanine: photodynamic activities in solid tumour models

Contact Info

Product

Resources

About